期刊
RESPIRATORY MEDICINE CASE REPORTS
卷 22, 期 -, 页码 197-202出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.rmcr.2017.08.017
关键词
Adenocarcinoma; Lung cancer; Immunotherapy; Nivolumab; Pembrolizumab; Programmed death-ligand
In this decade a bloom of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 >= 50% expression. (C) 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据